The trade-off pharmaceutical groups actually face when deciding how to structure a multi-market digital presence, and why the answer is rarely as binary as the question implies.
Global pharma brands eventually face the same architectural fork: run one global site with market-specific sections, or give each country its own site. The decision looks like a branding question, but it is really a governance and regulatory-divergence question — how much do approved claims, prescribing information, and competitive context actually vary market to market, and how much can your organisation govern well. Get it wrong in either direction and the failure mode is the same: markets forced into a template that doesn't fit them, or sites drifting apart with no technical relationship between them. This piece works through what each model actually solves, where each genuinely struggles, and the questions worth asking before committing to one.
A single global site with market-specific sections centralises governance: one platform to maintain, one set of templates to secure and update, and one brand system to enforce rather than a dozen local variants drifting slowly apart from it. The practical case for this model is strongest when the underlying business is simple to represent globally — a limited number of markets, similar regulatory status for the product across them, and no strong need for local teams to publish or adapt content independently of the global team. In that situation, a single site genuinely reduces cost and risk without asking any market to sacrifice much: there is little for them to sacrifice, because there isn’t much that needs to differ.
The same structure that makes a simple business easy to represent starts to strain once markets stop being simple. Markets with materially different regulatory content — different approved indications, different prescribing information, different permitted claims — or with distinct local competitive positioning, or with local teams that need real editorial autonomy to respond to their own market, all push against a template built for uniformity. A global site that forces every market into an identical structure can underserve markets that need materially different content or functionality, even when the platform appears consistent and well governed.
Separate country sites solve the opposite problem: genuine local relevance, and — when built correctly — clean separation of market-specific regulatory content, so that what’s approved and claimable in one market never bleeds into another. Local teams get real ownership of their own site rather than a fenced-off section of someone else’s, which is the same tension this site works through in more detail in local affiliate websites: affiliates are pulled between global’s need for consistency and the local market’s need for relevance, and a country-sites model is one way to resolve that pull in the local market’s favour.
The cost of that autonomy is governance overhead, and it does not scale linearly — it multiplies with every additional site, because each one is a separate platform, a separate content team, and a separate point where drift from the shared brand and regulatory standards can creep in unnoticed. Left uncoordinated, this is the most common cause of the internal competition problem covered in why do pharma websites have country gates, and corrected in multi-country architecture.
The pattern shows up often enough to be recognisable on sight: fifteen country sites with near-identical content, no declared technical relationship between them, all competing for the same search terms instead of reinforcing each other. The content itself is rarely the actual problem in these cases — the missing technical structure between the sites is.
Regardless of which model you choose, the technical targeting between versions of a page has to be declared correctly, or the choice of architecture stops mattering — see hreflang for pharma websites, per Google’s guidance on managing multi-regional and multilingual sites. A poorly implemented single global site and a poorly implemented set of country sites end up failing in similar ways: search engines and users alike lose track of which version is meant for whom. Conversely, a well-implemented version of either structure can work; the technical layer underneath is what actually determines whether the architecture holds together, not which of the two models you started from.
Companies default to treating this as a brand-consistency decision, but the variable that actually determines the right architecture is how much the approved claims and prescribing information genuinely differ from market to market. That single factor does more to predict the right structure than any preference the marketing team has for a unified look.
Before recommending one structure over the other, start with a short set of questions: how many markets are actually involved, how similar their regulatory status and approved claims are, how much local editorial autonomy is genuinely needed rather than merely wanted, and what your organisation can actually govern well in practice rather than in theory. The answer depends on those specifics far more than on either structure being categorically superior to the other.
Most workable answers sit between the two extremes rather than at either end of them: a shared global platform and design system, paired with genuine per-market content ownership for anything tied to local claims or positioning. That hybrid captures most of the efficiency of a single global site — one platform, one design system, one set of technical standards — without forcing markets with real regulatory divergence into a template that was never built to fit them.
There is no fixed number — regulatory divergence between markets is the variable that determines the right architecture, more than the raw count of markets involved. Low divergence in approved indications and claims supports one global site with market-specific sections, while high divergence in indications, standard of care or competitive context usually justifies more separation, even at some cost to brand uniformity.
Yes, though this is a full migration with real visibility risk attached, not a simple relaunch. Moving toward more shared architecture later tends to be more feasible than moving toward more separation later, which is worth weighing before committing to an initial structure that already involves uncertainty. See SEO migration for how that risk gets managed when the move happens.
That is a related but distinct decision, since it governs URL structure within whichever site model is chosen rather than the global-versus-country question itself. A subdirectory is the most common default for either model, while a ccTLD or subdomain gets reserved for markets with a specific reason for more technical separation. See subdirectory vs subdomain vs ccTLD for how that choice gets made.
It can, though not symmetrically — consolidating toward more shared architecture later tends to be more workable than splitting apart later, once separate sites, teams and platforms exist. That asymmetry is worth factoring into an initial decision that already carries some uncertainty, since choosing the direction that stays easier to reverse reduces the cost of getting it wrong the first time.
Tell us your markets and governance capacity and we will tell you which structure actually fits.